(Q37685601)

English

Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy

scientific article published on 08 July 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

22 August 2017

Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy (English)

1 reference

Europe PubMed Central

22 August 2017

0 references

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

18

object named as

Hagop M Kantarjian

1 reference

Europe PubMed Central

22 August 2017

Alessandra Ferrajoli

10

object named as

Alessandra Ferrajoli

1 reference

Europe PubMed Central

22 August 2017

6

object named as

Stefan Faderl

1 reference

Europe PubMed Central

22 August 2017

13

object named as

Zeev Estrov

1 reference

Europe PubMed Central

22 August 2017

4

object named as

Susan O'Brien

1 reference

Europe PubMed Central

22 August 2017

1

object named as

Farhad Ravandi

1 reference

Europe PubMed Central

22 August 2017

Jorge Eduardo Cortes

17

object named as

Jorge E Cortes

1 reference

Europe PubMed Central

22 August 2017

Rebecca S Garris

5

object named as

Rebecca Garris

1 reference

Europe PubMed Central

22 August 2017

Jeffrey C. Jorgensen

2

object named as

Jeffrey L Jorgensen

1 reference

Europe PubMed Central

22 August 2017

Richard E Champlin

12

object named as

Richard E Champlin

1 reference

Europe PubMed Central

22 August 2017

Partow Kebriaei

11

object named as

Partow Kebriaei

1 reference

Europe PubMed Central

22 August 2017

7

object named as

Xuelin Huang

1 reference

Europe PubMed Central

22 August 2017

Rajyalakshmi Luthra

16

object named as

Rajyalakshmi Luthra

1 reference

Europe PubMed Central

22 August 2017

8

object named as

Sijin Wen

1 reference

Europe PubMed Central

22 August 2017

Pramoda Challagundla

14

object named as

Pramoda Challagundla

1 reference

Europe PubMed Central

22 August 2017

9

object named as

Jan A Burger

1 reference

Europe PubMed Central

22 August 2017

author name string

Deborah A Thomas

3

1 reference

Europe PubMed Central

22 August 2017

Sa A Wang

15

1 reference

Europe PubMed Central

22 August 2017

language of work or name

0 references

publication date

8 July 2013

1 reference

Europe PubMed Central

22 August 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

22 August 2017

122

1 reference

Europe PubMed Central

22 August 2017

7

1 reference

Europe PubMed Central

22 August 2017

1214-1221

1 reference

Europe PubMed Central

22 August 2017

Chemotherapeutic agents circumvent emergence of dasatinib-resistant BCR-ABL kinase mutations in a precise mouse model of Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3976223

23 August 2017

How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3976223

23 August 2017

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3976223

23 August 2017

Standardized MRD quantification in European ALL trials: proceedings of the Second International Symposium on MRD assessment in Kiel, Germany, 18-20 September 2008.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3976223

23 August 2017

Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3976223

23 August 2017

Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3976223

23 August 2017

Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: results from the International

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3976223

23 August 2017

Advances in the management of Ph-positive ALL.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3976223

23 August 2017

Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3976223

23 August 2017

Current treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3976223

6 September 2017

Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3976223

6 September 2017

The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3976223

23 June 2018

High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3976223

23 June 2018

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3976223

1 September 2018

Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3976223

1 September 2018

Monitoring treatment response of childhood precursor B-cell acute lymphoblastic leukemia in the AIEOP-BFM-ALL 2000 protocol with multiparameter flow cytometry: predictive impact of early blast reduction on the remission status after induction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3976223

1 September 2018

Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3976223

1 September 2018

Isothermal multiple displacement amplification: a highly reliable approach for generating unlimited high molecular weight genomic DNA from clinical specimens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3976223

1 September 2018

TaqMan RT-PCR assay coupled with capillary electrophoresis for quantification and identification of bcr-abl transcript type.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3976223

1 September 2018

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3976223

1 September 2018

Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3976223

1 September 2018

Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3976223

1 September 2018

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia. European Organization for Research and Treatment of Cancer--Childhood Leukemia Cooperative Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3976223

1 September 2018

Multilineage involvement of Philadelphia chromosome positive acute lymphoblastic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23836561

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A limited antibody panel can distinguish B-precursor acute lymphoblastic leukemia from normal B precursors with four color flow cytometry: implications for residual disease detection

1 reference

https://pubmed.ncbi.nlm.nih.gov/23836561

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23836561

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Minimal residual disease in acute lymphoblastic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23836561

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies

1 reference

https://pubmed.ncbi.nlm.nih.gov/23836561

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Precise quantification of minimal residual disease at day 29 allows identification of children with acute lymphoblastic leukemia and an excellent outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/23836561

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/23836561

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparative analysis of Ig and TCR gene rearrangements at diagnosis and at relapse of childhood precursor-B-ALL provides improved strategies for selection of stable PCR targets for monitoring of minimal residual disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/23836561

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sequence analysis of clonal immunoglobulin and T-cell receptor gene rearrangements in children with acute lymphoblastic leukemia at diagnosis and at relapse: implications for pathogenesis and for the clinical utility of PCR-based methods of minimal r

1 reference

https://pubmed.ncbi.nlm.nih.gov/23836561

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2012-11-466482

1 reference

Europe PubMed Central

22 August 2017

1 reference

Europe PubMed Central

22 August 2017

1 reference

Europe PubMed Central

22 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37685601&oldid=1901884354"